A recent study published in *Nature Communications* by researchers at Mass General Brigham has identified plasma phosphorylated tau 217 (pTau217) as a promising biomarker for early detection of Alzheimer's disease. The study tracked 317 cognitively healthy adults aged 50 to 90 over an average of eight years, analyzing their blood markers, brain scans, and cognitive changes. It found that individuals with elevated pTau217 levels exhibited faster progression of Alzheimer's-related changes, sometimes even before abnormalities were visible on brain scans. Lead author Dr. Hyun-Sik Yang, a neurologist at Harvard Medical School, noted that traditional PET scans were previously considered the earliest sign of Alzheimer's, revealing amyloid accumulation 10 to 20 years prior to symptom onset. However, the detection of pTau217 offers a potential decade of additional warning time. With no current cure for Alzheimer's, this blood test could represent a critical advancement in early intervention strategies. The U.S. Food and Drug Administration is expected to clear a blood-based test for Alzheimer's by 2025, marking a significant shift towards less invasive diagnostic methods. However, access to such tests remains a challenge, particularly in countries like India, where specialist care is often limited to urban areas.